Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Bought by Verition Fund Management LLC

Verition Fund Management LLC lifted its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,285 shares of the biopharmaceutical company’s stock after acquiring an additional 2,927 shares during the quarter. Verition Fund Management LLC’s holdings in Vanda Pharmaceuticals were worth $189,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter worth about $39,000. ORG Wealth Partners LLC acquired a new stake in Vanda Pharmaceuticals during the third quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares in the last quarter. SG Americas Securities LLC acquired a new position in Vanda Pharmaceuticals in the second quarter worth approximately $61,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares during the period. Institutional investors own 88.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, December 11th. They issued a “hold” rating for the company. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.90% of the stock is owned by insiders.

Vanda Pharmaceuticals Trading Up 0.4 %

NASDAQ VNDA opened at $4.63 on Tuesday. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75. The company has a 50 day moving average of $4.84 and a 200-day moving average of $5.23. The firm has a market cap of $269.97 million, a price-to-earnings ratio of -16.54 and a beta of 0.76.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.